<!DOCTYPE html SYSTEM "about:legacy-compat">
<html class="no-js">
  <head>
    <meta charset="utf-8"/>
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
    <title>D.C. Law Library - Subchapter II. Standards and Schedules.</title>
    <meta property="st:title" content="Subchapter II. Standards and Schedules."/>
    <meta name="description" content="Browse the laws and code of the District of Columbia"/>
    <meta name="viewport" content="width=device-width"/>
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400italic,700italic,400,700" rel="stylesheet" type="text/css"/>
    <link rel="stylesheet" type="text/css" href="/css/main.css" media="screen"/>
    <link rel="stylesheet" type="text/css" href="/css/print.css" media="print"/>
    <script type="text/javascript">
        var _paq = _paq || [];
        _paq.push(['trackPageView']);
        _paq.push(['enableLinkTracking']);
        (function() {
            var u="//analytics.code.dccouncil.us/";
            _paq.push(['setTrackerUrl', u+'piwik.php']);
            _paq.push(['setSiteId', 1]);
            var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];
            g.type='text/javascript'; g.async=true; g.defer=true; g.src=u+'piwik.js'; s.parentNode.insertBefore(g,s);
        })();
        
        var xhttp = new XMLHttpRequest();
        xhttp.onreadystatechange = function() {
            if (this.readyState == 4 && this.status == 200) {
                let responseDOM = new DOMParser().parseFromString(this.responseText, 'text/html');
                let docInfo = document.getElementsByClassName("document-info")[0];
                let responseDocInfo = responseDOM.getElementsByClassName('document-info')[0];
                docInfo.insertBefore(responseDocInfo, docInfo.firstChild);
            }
        };
        xhttp.open("GET", "/dc/council/code/", true);
        xhttp.send();
        
        window.searchHost = 'https://search.code.dccouncil.us';
        window.queryUrl = '/v1/search';
    </script>
    <noscript>
      <p>
        <img src="//analytics.code.dccouncil.us/piwik.php?idsite=1" style="border:0;" alt=""/>
      </p>
    </noscript>
  </head>
  <body>
    <header>
      <section class="container">
        <a href="http://dccouncil.us">
          <img src="/css/header_logo.png" alt="DC Seal" class="header_logo"/>
        </a>
        <h1 id="sitename">
          <a href="/dc/council/code/">Code of the District of Columbia</a>
        </h1>
        <div class="right no-print search" id="search"> </div>
      </section>
    </header>
    <main class="main container">
      <div class="clearfix" style="width: 100%;">
        <aside id="sidebar" class="col3 quiet">
          <h2>You Are Here</h2>
          <ul class="ancestors">
            <li data-search-path="library" data-search-heading="All Documents">↪ <a href="/">D.C. Law Library</a></li>
            <li data-search-path="library|D.C. Code" data-search-heading="D.C. Code" data-search-default="true">↪ <a href="/dc/council/code/">Code of the District of Columbia</a></li>
            <li data-search-path="library|D.C. Code|48" data-search-heading="Title 48">↪ <a href="/dc/council/code/titles/48/">Title 48. Foods and Drugs.</a></li>
            <li data-search-path="library|D.C. Code|48|9" data-search-heading="Chapter 9">↪ <a href="/dc/council/code/titles/48/chapters/9/">Chapter 9. Controlled Substances Act.</a></li>
            <li data-search-path="library|D.C. Code|48|9|II" data-search-heading="Subchapter II">↪ Subchapter II. Standards and Schedules.</li>
          </ul>
          <h2>Previous</h2>
          <p>
            <a href="/dc/council/code/titles/48/chapters/9/subchapters/I/">Subchapter I. Definitions.</a>
          </p>
          <h2>Next</h2>
          <p>
            <a href="/dc/council/code/titles/48/chapters/9/subchapters/III/">Subchapter III. Regulation of Manufacture, Distribution, and Dispensing.</a>
          </p>
          <div class="document-info"/>
          <section class="cta">
            <p>
              <a href="mailto:code@dccouncil.us?subject=[ERROR]+/dc/council/code/titles/48/chapters/9/subchapters/II/">Report Error</a>
            </p>
            <p>
              <a href="mailto:code@dccouncil.us?subject=[FEEDBACK]+/dc/council/code/titles/48/chapters/9/subchapters/II/">Website Feedback</a>
            </p>
            <p>We cannot respond to questions regarding the law.</p>
          </section>
        </aside>
        <section class="col8 body">
          <h1 id="/dc/council/code/titles/48/chapters/9/subchapters/II/">Subchapter II. Standards and Schedules.</h1>
          <section class="line-group toc child-link">
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.01.html">§ 48–902.01. Administration.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.02.html">§ 48–902.02. Nomenclature.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.03.html">§ 48–902.03. Schedule I tests.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.04.html">§ 48–902.04. Schedule I enumerated.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.05.html">§ 48–902.05. Schedule II tests.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.06.html">§ 48–902.06. Schedule II enumerated.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.07.html">§ 48–902.07. Schedule III tests.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.08.html">§ 48–902.08. Schedule III enumerated.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.09.html">§ 48–902.09. Schedule IV tests.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.10.html">§ 48–902.10. Schedule IV enumerated.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.11.html">§ 48–902.11. Schedule V tests.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.12.html">§ 48–902.12. Schedule V enumerated.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.13.html">§ 48–902.13. Revising and republishing of schedules.</a>
            </p>
            <p class="toc-link-container">
              <a href="/dc/council/code/sections/48-902.14.html">§ 48–902.14. Treatment of controlled substance analogues.</a>
            </p>
          </section>
          <section class="content">
            <hr/>
            <h1>§ 48–902.01. Administration.</h1>
            <section>
              <section class="line-group primary-content">
                <p class="text-indent-1"><span class="level-num" id="(a)">(a)</span> The Mayor shall administer this chapter and, with provision for public notice and comment, may add substances to or delete or reschedule all substances enumerated in the schedules in <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.04.html">§ 48-902.04</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.06.html">§ 48-902.06</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.08.html">§ 48-902.08</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.10.html">§ 48-902.10</a> or <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.12.html">§ 48-902.12</a> pursuant to <a class="internal-link " href="/dc/council/code/titles/2/chapters/5/subchapters/I/">subchapter I of Chapter 5 of Title 2</a> and pursuant to the procedures set forth in this chapter. In making a determination regarding a substance, the Mayor shall consider the following:</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(1)">(1)</span> The actual or relative potential for abuse;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(2)">(2)</span> The scientific evidence of its pharmacological effect, if known;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(3)">(3)</span> The state of current scientific knowledge regarding the substance;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(4)">(4)</span> The history and current pattern of abuse;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(5)">(5)</span> The scope, duration, and significance of abuse;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(6)">(6)</span> The risk to the public health;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(7)">(7)</span> The potential of the substance to produce psychological or physiological dependence; and</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(8)">(8)</span> Whether the substance is an immediate precursor of a substance already controlled under this subchapter.</p>
                <p class="text-indent-1"><span class="level-num" id="(b)">(b)</span> After considering the factors enumerated in subsection (a) of this section and after complying with <a class="internal-link " href="/dc/council/code/titles/2/chapters/5/subchapters/I/">subchapter I of Chapter 5 of Title 2</a>, the Mayor shall make findings with respect to the factors and issue a rule either controlling the substance if the Mayor finds that the substance has a potential for abuse or deleting the substance if the Mayor finds that the substance does not have a potential for abuse.</p>
                <p class="text-indent-1"><span class="level-num" id="(c)">(c)</span> If the Mayor designates a substance as an immediate precursor, substances which are precursors of the controlled precursor shall not be subject to control solely because they are precursors of the controlled precursor.</p>
                <p class="text-indent-1"><span class="level-num" id="(d)">(d)</span> If any substance is designated, rescheduled, or deleted as a controlled substance under federal law, the Mayor may similarly designate, reschedule, or delete the controlled substance under this chapter, or may otherwise designate, reschedule or delete as a controlled substance pursuant to subsections (a) and (b) of this section.</p>
                <p class="text-indent-1"><span class="level-num" id="(e)">(e)</span> Authority to control under this section does not extend to tobacco or to distilled spirits, wine, or malt beverages, as those terms are defined or used in <a class="internal-link no-wrap" href="/dc/council/code/sections/25-103.html">§ 25-103</a>.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§201" title="§ 201.">Aug. 5, 1981, D.C. Law 4-29, § 201, 28 DCR 3081</a>; <a class="internal-link" href="/dc/council/laws/6-15.html" title="D.C. Law 6-15.">Aug. 1, 1985, D.C. Law 6-15, § 5, 32 DCR 3570</a>; <a class="internal-link" href="/dc/council/laws/12-136.html" title="D.C. Law 12-136. Uniform Controlled Substances Amendment Act of 1998.">July 24, 1998, D.C. Law 12-136, § 2(a), 45 DCR 2942</a>; <a class="internal-link" href="/dc/council/laws/19-320.html" title="D.C. Law 19-320. Omnibus Criminal Code Amendments Act of 2012.">June 19, 2013, D.C. Law 19-320, § 301(a), 60 DCR 3390</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-511.</p>
                <h4>Section References</h4>
                <p>This section is referenced in <a class="internal-link no-wrap" href="/dc/council/code/sections/22-2603.01.html">§ 22-2603.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-901.02.html">§ 48-901.02</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.04.html">§ 48-902.04</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.06.html">§ 48-902.06</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.08.html">§ 48-902.08</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.10.html">§ 48-902.10</a>, and <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.12.html">§ 48-902.12</a>.</p>
                <h4>Effect of Amendments</h4>
                <p>The 2013 amendment by <a class="internal-link " href="/dc/council/laws/19-320.html">D.C. Law 19-320</a>, in (d), substituted “the Mayor may similarly designate, reschedule, or delete the controlled substance” for “the Mayor may similarly propose to control or delete the substance” and added “or may otherwise designate, reschedule or delete as a controlled substance”.</p>
                <h4>Emergency Legislation</h4>
                <p>For temporary (90 days) amendment of this section, see § 301(a) of the Omnibus Public Safety and Justice Amendment Act of 2012 (D.C. Act 19-599, January 14, 2013, 60 DCR 1017).</p>
                <p>For temporary (90 days) amendment of (d), see § 301(a) of the Omnibus Criminal Code Amendments Congressional Review Emergency Amendment Act of 2013 (D.C. Act 20-44, April 1, 2013,  60 DCR 5381, 20 DCSTAT 1281).</p>
                <h4>References in Text</h4>
                <p>Section 25-103, referred to in subsection (e) of this section, is part of Title 25, D.C. Official Code, which title was amended and enacted by <a class="internal-link " href="/dc/council/laws/13-298.html">D.C. Law 13-298</a>, effective May 3, 2001. For disposition of the subject matter of former Title 25, see the Disposition Table preceding <a class="internal-link no-wrap" href="/dc/council/code/sections/25-101.html">§ 25-101</a>.</p>
                <h4>Editor's Notes</h4>
                <p>Pursuant to subsection (b), sufentanil was added to the list of enumerated controlled substances in Schedule II, appearing in subparagraph (A) of paragraph (1) of <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.06.html">§ 48-902.06</a>, by an order published upon adoption of the rule in  32 DCR 1097.</p>
                <p>Pursuant to subsection (b), buprenorphine was rescheduled from Schedule II to Schedule V of enumerated controlled substances appearing in <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.12.html#(3)">§ 48-902.12(3)</a>, by an order published upon adoption of the rule in  33 DCR 6908.</p>
                <p>Pursuant to subsection (b), loperamide was deleted from Schedule V appearing in <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.12.html#(3)">§ 48-902.12(3)</a> by an order published upon adoption of the rule in  34 DCR 4370.</p>
                <h4>Delegation of Authority</h4>
                <p>Delegation of Authority to implement <a class="internal-link " href="/dc/council/laws/4-29.html">D.C. Law 4-29</a>, the “District of Columbia Uniformed Controlled Substances Act of 1981”, see Mayor’s Order 98-49, April 15, 1998 ( 45 DCR 2694).</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.02. Nomenclature.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The controlled substances listed or to be listed in the schedules in §§ <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.04.html">48-902.04</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.06.html">48-902.06</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.08.html">48-902.08</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.10.html">48-902.10</a> and <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.12.html">48-902.12</a> are included by whatever official, common, usual, chemical, or trade name designated.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§202" title="§ 202.">Aug. 5, 1981, D.C. Law 4-29, § 202, 28 DCR 3081</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-512.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.03. Schedule I tests.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The Mayor shall place a substance in Schedule I if the Mayor finds that the substance:</p>
                <p class="text-indent-2"><span class="level-num" id="(1)">(1)</span> Has high potential for abuse; and</p>
                <p class="text-indent-2"><span class="level-num" id="(2)">(2)</span> Has no accepted medical use in treatment in the United States or in the District of Columbia or lacks accepted safety for use in treatment under medical supervision.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§203" title="§ 203.">Aug. 5, 1981, D.C. Law 4-29, § 203, 28 DCR 3081</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-513.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.04. Schedule I enumerated.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The controlled substances listed in this section are included in Schedule I, unless and until removed therefrom pursuant to <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>:</p>
                <p class="text-indent-2"><span class="level-num" id="(1)">(1)</span> Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)">(A)</span> Acetylmethadol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(B)">(B)</span> Allylprodine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(C)">(C)</span> Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alphaacetylmethadol, levomethadyl, accetate, or LAAM);</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(D)">(D)</span> Alphameprodine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(E)">(E)</span> Alphamethadol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(F)">(F)</span> Benzethidine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(G)">(G)</span> Betacetylmethadol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(H)">(H)</span> Betameprodine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(I)">(I)</span> Betamethadol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(J)">(J)</span> Betaprodine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(K)">(K)</span> Clonitazene;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(L)">(L)</span> Dextromoramide;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(M)">(M)</span> Diampromide;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(N)">(N)</span> Diethylthiambutene;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(O)">(O)</span> Difenoxin;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(P)">(P)</span> Dimenoxadol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(Q)">(Q)</span> Dimepheptanol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(R)">(R)</span> Dimethylthiambutene;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(S)">(S)</span> Dioxaphetylbutyrate;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(T)">(T)</span> Dipipanone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(U)">(U)</span> Ethylmethylthiambutene;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(V)">(V)</span> Etonitazene;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(W)">(W)</span> Etoxeridine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(X)">(X)</span> Furethidine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(Y)">(Y)</span> Hydroxypethidine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(Z)">(Z)</span> Ketobemidone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(AA)">(AA)</span> Levomoramide;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(BB)">(BB)</span> Levophenacylmorphan;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(CC)">(CC)</span> Morpheridine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(DD)">(DD)</span> Noracymethadol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(EE)">(EE)</span> Norlevorphanol;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(FF)">(FF)</span> Normethadone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(GG)">(GG)</span> Norpipanone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(HH)">(HH)</span> Phenadoxone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(II)">(II)</span> Phenampromide;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(JJ)">(JJ)</span> Phenomorphan;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(KK)">(KK)</span> Phenoperidine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(LL)">(LL)</span> Piritramide;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(MM)">(MM)</span> Proheptazine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(NN)">(NN)</span> Properidine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(OO)">(OO)</span> Propiram;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(PP)">(PP)</span> Racemoramide;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(QQ)">(QQ)</span> Thiophene;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(RR)">(RR)</span> Trimeperidine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(SS)">(SS)</span> Acetyl-Alpha-Methylfentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(TT)">(TT)</span> Alphe-methylfentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(UU)">(UU)</span> Alpha-Methylthiofentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(VV)">(VV)</span> Beta-hydroxyfentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(WW)">(WW)</span> Beta-hydroxy-3-Methylfentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(XX)">(XX)</span> 3-Methylfentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(YY)">(YY)</span> 3-Methylthiofentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(ZZ)">(ZZ)</span> MPPP;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(AAA)">(AAA)</span> Para-flurofentanyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(BBB)">(BBB)</span> PEPAP;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(CCC)">(CCC)</span> Thiofentanyl; and</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(DDD)">(DDD)</span> Tilidine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)">(2)</span> Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(A)">(A)</span> Acetorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(B)">(B)</span> Acetyldihydrocodeine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(C)">(C)</span> Benzylmorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(D)">(D)</span> Codeine methylbromide;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(E)">(E)</span> Codeine-N-Oxide;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(F)">(F)</span> Cyprenorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(G)">(G)</span> Desomorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(H)">(H)</span> Dihydromorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(I)">(I)</span> Drotepanol;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(J)">(J)</span> Etorphine (except hydrochloride salt);</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(K)">(K)</span> Diacetylated morphine (heroin);</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(L)">(L)</span> Hydromorphinol;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(M)">(M)</span> Methyldesorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(N)">(N)</span> Methyldihydromorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(O)">(O)</span> Morphine methylbromide;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(P)">(P)</span> Morphine methylsulfonate;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(Q)">(Q)</span> Morphine-N-Oxide;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(R)">(R)</span> Myrophine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(S)">(S)</span> Nicocodeine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(T)">(T)</span> Nicomorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(U)">(U)</span> Normorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(V)">(V)</span> Pholcodine; and</p>
                <p class="text-indent-3"><span class="level-num" id="(2)(W)">(W)</span> Thebacon;</p>
                <p class="text-indent-2"><span class="level-num" id="(3)">(3)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, its salts, isomers and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation :</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(A)">(A)</span> 4-bromo-2, 5-dimethoxyamphetamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(B)">(B)</span> 2, 5 dimethoxyamphetamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(C)">(C)</span> 4-methoxyamphetamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(D)">(D)</span> 5-methoxy-3, 4-methylenedioxy amphetamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(E)">(E)</span> 4-methyl-2,5-dimethoxyamphetamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(F)">(F)</span> 3,4-methylenedioxyamphetamine [MDA];</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G)">(G)</span> 3, 4, 5-trimethoxy amphetamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-i)">(G-i)</span> 25I-NBOMe (also known as 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-ii)">(G-ii)</span> 25B-NBOMe (also known as 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine)</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-iii)">(G-iii)</span> 25C-NBOMe (also known as 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-iv)">(G-iv)</span> 5-APB (also known as α-methyl-5-benzofuranethanamine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-v)">(G-v)</span> 5-APDB (also known as 2,3-dihydro-α-methyl-5-benzofuranethanamine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-vi)">(G-vi)</span> 6-APB (also known as α-methyl-6-benzofuranethanamine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-vii)">(G-vii)</span> 6-APDB (also known as 2,3-dihydro-α-methyl-6-benzofuranethanamine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-viii)">(G-viii)</span> 3-methoxy-PCE (also known as N-ethyl-1-(3-methoxyphenyl)-cyclohexanamine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-ix)">(G-ix)</span> 3-methoxy-PCP (also known as 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-x)">(G-x)</span> 4-methoxy-PCP (also known as 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-xi)">(G-xi)</span> 5-methoxy-DALT, also known as:</p>
                <p class="text-indent-4"><span class="level-num" id="(3)(G-xi)(i)">(i)</span> 5-MeO-DALT; or</p>
                <p class="text-indent-4"><span class="level-num" id="(3)(G-xi)(ii)">(ii)</span> 5-methoxy-N,N-di-2-propen-1-yl-1H-indole-3-ethanamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(G-xii)">(G-xii)</span> 4-acetoxy DMT, also known as:</p>
                <p class="text-indent-4"><span class="level-num" id="(3)(G-xii)(i)">(i)</span> 4-AcO-DMT; or</p>
                <p class="text-indent-4"><span class="level-num" id="(3)(G-xii)(ii)">(ii)</span> 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol-4-acetate;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(H)">(H)</span> Bufotenine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(I)">(I)</span> Diethyltryptamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(J)">(J)</span> Dimethyltryptamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(K)">(K)</span> Ethylamide analog of phencyclidine, PCE;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(L)">(L)</span> Ibogaine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(M)">(M)</span> Lysergic acid diethylamide;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(M-i)">(M-i)</span> Methoxetamine (also known as 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(N)">(N)</span> Mescaline;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(O)">(O)</span> Peyote;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(P)">(P)</span> N-ethyl-3-piperidyl benzilate;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(Q)">(Q)</span> N-methyl-3-piperidyl benzilate;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(R)">(R)</span> Psilocybin;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(S)">(S)</span> Psilocyn;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(T)">(T)</span> Pyrrolidine analog of phencyclidine, PCPY;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(U)">(U)</span> Thiophene analog of phencyclidine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(V)">(V)</span> Repealed;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(W)">(W)</span> Parahexyl;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(X)">(X)</span> 4-bromo-2,5-dimethoxyphenethylamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(Y)">(Y)</span> 3,4-methylenedioxymethamphetamine [MDMA];</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(Z)">(Z)</span> Alpha-methyltryptamine (other name: AMT);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(AA)">(AA)</span> 5-methoxy-N,N-diisopropyltryptamine (other name: 5- MeO-DIPT);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(BB)">(BB)</span> 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(CC)">(CC)</span> 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(DD)">(DD)</span> 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(EE)">(EE)</span> 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(FF)">(FF)</span> 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(GG)">(GG)</span> 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(HH)">(HH)</span> 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C- T-4);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(II)">(II)</span> 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(JJ)">(JJ)</span> 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(KK)">(KK)</span> 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); and</p>
                <p class="text-indent-3"><span class="level-num" id="(3)(LL)">(LL)</span> Cathinone;</p>
                <p class="text-indent-2"><span class="level-num" id="(4)">(4)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, or mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(4)(A)">(A)</span> Mecloqualone;</p>
                <p class="text-indent-3"><span class="level-num" id="(4)(B)">(B)</span> Methaqualone; and</p>
                <p class="text-indent-3"><span class="level-num" id="(4)(C)">(C)</span> Gamma-hydroxybutyric acid (some other names include GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);</p>
                <p class="text-indent-2"><span class="level-num" id="(5)">(5)</span> As used in this paragraph, the term "synthetic cathinones" includes any material, compound, mixture, or preparation that is not otherwise listed as a controlled substance in this schedule or in Schedules II through V, is not approved by the Food and Drug Administration as a drug, and is structurally derived from or contains any quantity of the following substances, their salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(5)(A)">(A)</span> Classified Synthetic Cathinones:</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(A)(i)">(i)</span> Cathinones. Any compound, other than methylnenedioxy cathinones and pyrrolidine cathinones, containing a 2-amino-1-propanone structure with substitution at the 1-position with a monocyclic ring system, with or without alkyl, alkoxyl, or halo substitutions, and a substitution at the nitrogen atom by an alkyl group, cycloalkyl group, or incorporation into a heterocyclic structure. Examples of this structural class include:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(I)">(I)</span> Mephedrone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(I)(aa)">(aa)</span> 2-(methylamino )-1-(4-methylphenyl)-1-propanone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(I)(bb)">(bb)</span> 4-MeMC;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(I)(cc)">(cc)</span> 4-Methylmethcathinone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(I)(dd)">(dd)</span> 4-Methylephedrone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(I)(ee)">(ee)</span> 4-MMC;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(II)">(II)</span> Dimethylcathinone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(II)(aa)">(aa)</span> 2-(dimethylamino)-1-phenyl-1-propanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(II)(bb)">(bb)</span> N,N-Dimethylcathinone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(III)">(III)</span> Ethcathinone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(III)(aa)">(aa)</span> 2-(ethylamino)-1-phenyl-1-propanone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(III)(bb)">(bb)</span> Ethylcathinone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(III)(cc)">(cc)</span> N-Ethylcathinone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(III)(dd)">(dd)</span> 2-Ethylaminobuphedro;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(IV)">(IV)</span> Buphedrone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(IV)(aa)">(aa)</span> 2-(methylamino)-1-phenylbutan-l-one; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(IV)(bb)">(bb)</span> MABP;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(V)">(V)</span> 3,4-DMMC, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(V)(aa)">(aa)</span> 1-(3,4-dimethylphenyl)-2-(methylamino)-1- propanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(V)(bb)">(bb)</span> 3,4-Dimethylmethcathinone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(VI)">(VI)</span> EMC, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(VI)(aa)">(aa)</span> 1-(4-ethylphenyl)-2-(methylamino)propan-1-one;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(VI)(bb)">(bb)</span> 4-EMC; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(VI)(cc)">(cc)</span> 4-Ethylmethcathinone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(VII)">(VII)</span> Fluoromethcathinone (also known as 1-(4-fluorophenyl)-2-(methylamino) propan-1-one);</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(VIII)">(VIII)</span> 3-FMC, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(VIII)(aa)">(aa)</span> 3-fluoro-N-methylcathinone); or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(VIII)(bb)">(bb)</span> 1-(3-fluorophenyl)-2-(methylamino)propan-1- one;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(IX)">(IX)</span> 4-FMC, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(IX)(aa)">(aa)</span> 1-(4-fluorophenyl)-2-(methylamino)propan-1-one;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(IX)(bb)">(bb)</span> 4-fluoro-N-methylcathinone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(IX)(cc)">(cc)</span> Flephedrone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(X)">(X)</span> 4-MeBP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(X)(aa)">(aa)</span> 2-(methylamino)-1-(4-methylphenyl)-1-butanone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(X)(bb)">(bb)</span> 4-Methylbuphedrone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(X)(cc)">(cc)</span> 4-methyl BP; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(X)(dd)">(dd)</span> 4-MeMABP;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(XI)">(XI)</span> 3-MEC, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(XI)(aa)">(aa)</span> 2-(ethylamino )-1-(m-tolyl)propan-l-one; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(XI)(bb)">(bb)</span> 3-Methyl-N-ethylcathinone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(XII)">(XII)</span> 4-MEC, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(XII)(aa)">(aa)</span> 2-(ethylamino)-1-(4-methylphenyl)-1-propanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(XII)(bb)">(bb)</span> 4-Methyl-N-ethylcathinone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(XIII)">(XIII)</span> 3-MMC, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(XIII)(aa)">(aa)</span> 2-(methylamino)-1-(3-methylphenyl)-1-propanone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(XIII)(bb)">(bb)</span> 3-methyl MS; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(i)(XIII)(cc)">(cc)</span> 3-Methylmethcathinone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(XIV)">(XIV)</span> Methedrone (also known as l-(4-methoxyphenyl)-2-(methylamino)-1-propanone); and</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(i)(XV)">(XV)</span> Pentedrone (also known as 2-(methylamino)-1-phenylpentan-1-one);</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(A)(ii)">(ii)</span> Methylenedioxy Cathinones. Any compound containing a 2- amino-1-propanone structure with substitution at the 1-position with a monocyclic or fused polycyclic ring system and a substitution at any position of the ring system with an alkyl, haloalkyl, halogen, alkylenedioxy, or alkoxy group, whether or not further substituted at any position on the ring system to any extent. Examples of this structural class include:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(ii)(I)">(I)</span> 3-fluoromethylone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(ii)(II)">(II)</span> Methylone, also known as</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(II)(aa)">(aa)</span> 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-propanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(II)(bb)">(bb)</span> 3,4-Methylenedioxy-N-methylcathinone);</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(ii)(III)">(III)</span> N-ethyl Pentylone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(III)(aa)">(aa)</span> Ephylone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(III)(bb)">(bb)</span> 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(ii)(IV)">(IV)</span> bk-MDDMA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(IV)(aa)">(aa)</span> 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(IV)(bb)">(bb)</span> Dimethylone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(IV)(cc)">(cc)</span> N,<em>N</em>-dimethyl-3',4'-methylenedioxycathinone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(IV)(dd)">(dd)</span> N,<em>N</em>-dimethyl-3,4-methylenedioxycathinone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(IV)(ee)">(ee)</span> N,N-Dimethyl MDCATH;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(ii)(V)">(V)</span> Butylone, also known as 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one); and</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(ii)(VI)">(VI)</span> Ethylone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(VI)(aa)">(aa)</span> 3,4-Methylenedioxy-N-ethylcathinone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(ii)(VI)(bb)">(bb)</span> MDEC;</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(A)(iii)">(iii)</span> Pyrrolidine Cathinones. Any compound containing a 2-amino-1-propanone structure with substitution at the 1-position with an alkyl, cyclic, or fused polycyclic ring system and a substitution at the 3-position carbon with an alkyl, haloalkyl, halogen, alkoxy or alkylenedioxy group, and a substitution at the nitrogen atom incorporation into a heterocyclic structure, with or without further halogen substitutions. Examples include:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(I)">(I)</span> α-PVP (also known as α-pyrrolidinopentiophenone);</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(II)">(II)</span> α-pyrrolidinopropiophenone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(II)(aa)">(aa)</span> 1-phenyl-2-(1-pyrrolidinyl)-l-propanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(II)(bb)">(bb)</span> α-PPP;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(III)">(III)</span> α-PBP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(III)(aa)">(aa)</span> 1-phenyl-2-(1-pyrrolidinyl)-1-butanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(III)(bb)">(bb)</span> α-pyrrolidinobutiophenone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(IV)">(IV)</span> MDPBP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(IV)(aa)">(aa)</span> 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-butanone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(IV)(bb)">(bb)</span> 3,4-Methylenedioxy-α-Pyrrolidinobutiophenone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(IV)(cc)">(cc)</span> 3,4-MDPBP;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(V)">(V)</span> MDPPP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(V)(aa)">(aa)</span> 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-propanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(V)(bb)">(bb)</span> 3,4-Methylenedioxy-α-Pyrrolidinopropiophenone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(VI)">(VI)</span> MDPV, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VI)(aa)">(aa)</span> 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VI)(bb)">(bb)</span> 3,4-Methylenedioxy Pyrovalerone;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(VII)">(VII)</span> 4-MePPP, also known as</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VII)(aa)">(aa)</span> 4'-methyl-α-Pyrrolidinopropiophenone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VII)(bb)">(bb)</span> 4'-methyl PPP; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VII)(cc)">(cc)</span> 2-(pyrrolidin-l-yl)-1-(p-tolyl)propan-l-one;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(VIII)">(VIII)</span> 4'-methyl PHP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VIII)(aa)">(aa)</span> 4'-methyl-α-pyrrolidinohexanophenone;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VIII)(bb)">(bb)</span> MPHP;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VIII)(cc)">(cc)</span> 4'-methyl-α-PHP; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(VIII)(dd)">(dd)</span> PV4;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(IX)">(IX)</span> Naphyrone, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(IX)(aa)">(aa)</span> (RS)-1-naphthalen-2-yl-2-pyrrolidin-l- ylpentan-1-one; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(IX)(bb)">(bb)</span> Naphpyrovalerone; and</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iii)(X)">(X)</span> C-PVP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(X)(aa)">(aa)</span> 4-Chloro-α-PVP; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iii)(X)(bb)">(bb)</span> 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan- 1-one; or</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(A)(iv)">(iv)</span> Piperazine Stimulants. Any compound containing or structurally derived from a piperazine, or diethylenediamine, structure with or without substitution at one of the nitrogen atoms of the piperazine ring to any extent, including alkyl, cycloalkyl, or fused ring systems, with or without further halogen substitutions. Examples include:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iv)(I)">(I)</span> BZP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iv)(I)(aa)">(aa)</span> 1-(phenylmethyl)-piperazine;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iv)(I)(bb)">(bb)</span> 1-Benzylpiperazine; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iv)(I)(cc)">(cc)</span> N-Benzylpiperazine; and</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(A)(iv)(II)">(II)</span> TMFPP, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iv)(II)(aa)">(aa)</span> 1-[3-(trifluoromethyl)phenyl]-piperazine;</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iv)(II)(bb)">(bb)</span> 1-(m-Trifluoromethylphenyl) piperazine; or</p>
                <p class="text-indent-6"><span class="level-num" id="(5)(A)(iv)(II)(cc)">(cc)</span> 3-Trifluoromethylphenylpiperazine.</p>
                <p class="text-indent-3"><span class="level-num" id="(5)(B)">(B)</span> Unclassified Synthetic Cathinones:</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(B)(i)">(i)</span> Aminorex (also known as (RS)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine);</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(B)(ii)">(ii)</span> α-ET, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(ii)(I)">(I)</span> α-ethyl-1H-indole-3-ethanamine;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(ii)(II)">(II)</span> α-ethyltryptamine; or</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(ii)(III)">(III)</span> 3-Indolybutylamine;</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(B)(iii)">(iii)</span> α-MT, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(iii)(I)">(I)</span> α-methyl-1H-indole-3-ethanamine; or</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(iii)(II)">(II)</span> α-methyltryptamine;</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(B)(iv)">(iv)</span> EMA, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(iv)(I)">(I)</span> N-ethyl-α-methyl-benzeneethanamine; or</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(iv)(II)">(II)</span> N-Ethylamphetamine;</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(B)(v)">(v)</span> Fenethylline (also known as (RS)-1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino)ethyl]purine-2,6-dione);</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(B)(vi)">(vi)</span> N-hydroxy MDA, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(vi)(I)">(I)</span> MDOH;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(vi)(II)">(II)</span> N-hydroxy-α-methyl-1,3-benzodioxole-5-ethanamine;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(vi)(III)">(III)</span> N-Hydroxy-3,4-methylenedioxyamphetamine; and</p>
                <p class="text-indent-4"><span class="level-num" id="(5)(B)(vii)">(vii)</span> N,N-DMA, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(vii)(I)">(I)</span> N,N,α-trimethyl-benzeethanamine;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(vii)(II)">(II)</span> N,N-Dimethylamphetamine;</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(vii)(III)">(III)</span> Dimetamfetamine; or</p>
                <p class="text-indent-5"><span class="level-num" id="(5)(B)(vii)(IV)">(IV)</span> Metrotonin.</p>
                <p class="text-indent-2"><span class="level-num" id="(6)">(6)</span> Synthetic cannabimimetic agents (also known as "synthetic cannabinoids"), which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(6)(A)">(A)</span> Classified Synthetic Cannabimimetic Agents:</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(i)">(i)</span> Adamantanoylindoles: Any compound containing or structurally derived from  an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(i)(I)">(I)</span> AB-001, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(i)(I)(aa)">(aa)</span> (1s,3s)-adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(i)(I)(bb)">(bb)</span> JWH 018 adamantyl analog; and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(i)(II)">(II)</span> AM-1248, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(i)(II)(aa)">(aa)</span> [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]tricyclo[3.3.1.13,7]dec-1-yl-methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(i)(II)(bb)">(bb)</span> AM1248;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(ii)">(ii)</span> Benzimidazole Ketone: Any compound containing or structurally derived from (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.  Benzimidazole Ketones include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(ii)(I)">(I)</span> FUBIMINA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(ii)(I)(aa)">(aa)</span> (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(ii)(I)(bb)">(bb)</span> AM2201 benzimidazole analog; and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(ii)(II)">(II)</span> JWH-018 benzimidazole analog, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(ii)(II)(aa)">(aa)</span> naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(ii)(II)(bb)">(bb)</span> BIM-018;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(iii)">(iii)</span> Benzoylindoles: Any compound containing or structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(I)">(I)</span> AM-630, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(I)(aa)">(aa)</span> [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(I)(bb)">(bb)</span> AM630; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(I)(cc)">(cc)</span> Iodopravadoline ;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(II)">(II)</span> AM-661 (also known as 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(III)">(III)</span> AM-679, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(III)(aa)">(aa)</span> (2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(III)(bb)">(bb)</span> AM679;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(IV)">(IV)</span> AM-694, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(IV)(aa)">(aa)</span> [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(IV)(bb)">(bb)</span> 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(IV)(cc)">(cc)</span> AM694;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(V)">(V)</span> AM-1241, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(V)(aa)">(aa)</span> (2-iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(V)(bb)">(bb)</span> AM1241;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(VI)">(VI)</span> AM-2233, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(VI)(aa)">(aa)</span> (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(VI)(bb)">(bb)</span> AM2233;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(VII)">(VII)</span> RCS-4, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(VII)(aa)">(aa)</span> (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(VII)(bb)">(bb)</span> SR-19; and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(iii)(VIII)">(VIII)</span> WIN 48,098, also known as</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(VIII)(aa)">(aa)</span> (4-methoxyphenyl)[2-methyl]-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(iii)(VIII)(bb)">(bb)</span> "Pravadoline";</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(iv)">(iv)</span> Carbazole Ketone: Any compound containing or structurally derived from (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples include EG-018 (also known as naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(v)">(v)</span> Indazole Amide: Any compound containing or structurally derived from 3-carboxamide-lH-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen. Examples include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(I)">(I)</span> AB-CHMINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(II)">(II)</span> AB-FUBINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(III)">(III)</span> AB-PINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(IV)">(IV)</span> 5F AB-PINACA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(IV)(aa)">(aa)</span> N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(IV)(bb)">(bb)</span> 5-fluoro AB-PINACA;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(V)">(V)</span> ADB-FUBINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1-H-indazole-3-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(VI)">(VI)</span> ADB-PINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-l-pentyl-1H-indazole-3-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(VII)">(VII)</span> 5F ADB-PINACA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(VII)(aa)">(aa)</span> N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(VII)(bb)">(bb)</span> 5-fluoro ADB-PINACA;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(VIII)">(VIII)</span> FUB-AMB, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(VIII)(aa)">(aa)</span> methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(VIII)(bb)">(bb)</span> AMB-FUBINACA; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(VIII)(cc)">(cc)</span> MMB-FUBINACA;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(IX)">(IX)</span> 5-fluoro-AMB (also known as (S)-methyl 2-(1-(5-fluoropentyl)-lH-indazole-3-carboxamido)-3-methylbutanoate);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(X)">(X)</span> MAB-CHMINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide );</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(XI)">(XI)</span> MMB CHMINACA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XI)(aa)">(aa)</span> methyl (S)-2-(l-(cyclohexylmethyl)-IH-indole-3-carboxamido )-3,3-dimethylbutanoate; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XI)(bb)">(bb)</span> MDMB-CHMICA;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(XII)">(XII)</span> 5F MN-18, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XII)(aa)">(aa)</span> 1-(5-fluoropentyl)-N-1-naphthalenyl-IH-indazole-3-carboxamide; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XII)(bb)">(bb)</span> 5-fluoro MN-18;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(XIII)">(XIII)</span> 5F-APINACA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIII)(aa)">(aa)</span> 5-fluoro-APINACA</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIII)(bb)">(bb)</span> 5F-AKB-48;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIII)(cc)">(cc)</span> 5F-AKB48;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIII)(dd)">(dd)</span> N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIII)(ee)">(ee)</span> N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(v)(XIV)">(XIV)</span> APINACA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIV)(aa)">(aa)</span> AKB-48;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIV)(bb)">(bb)</span> AKB48;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIV)(cc)">(cc)</span> 1-pentyl-N-tricyclo[3.3.l .13,7]dec-1-yl-1H-indazole-3-carboxamide; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(v)(XIV)(dd)">(dd)</span> N-(1-adamantyl)-1-pentyl-l<em>H</em>-indazole-3-carboxamide;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(vi)">(vi)</span> Cyclohexylphenols: Any compound containing or structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent.  Examples include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vi)(I)">(I)</span> CP 47,497 (also known as 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vi)(II)">(II)</span> CP 47,497 C8 homologue, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vi)(II)(aa)">(aa)</span> rel-2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylnonan-2-yl)phenol; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vi)(II)(bb)">(bb)</span> Cannabicyclohexanol;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vi)(III)">(III)</span> CP 55,490;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vi)(IV)">(IV)</span> CP 55,940 (also known as 5-(1,1-dimethylheptyl)-2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vi)(V)">(V)</span> CP 56,667;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(vii)">(vii)</span> Cyclopropanoylindoles: Any compound containing or structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent. Cyclopropanoylindoles include cyclopropylmethanone indoles, as well as other cycloalkanemethanones, whether or not substituted at the nitrogen atom on the indole ring, whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cycloalkane ring to any extent. Examples of this structural class include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(I)">(I)</span> A-796,260, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(I)(aa)">(aa)</span> [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(I)(bb)">(bb)</span> A-796260;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(II)">(II)</span> A-834,735, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(II)(aa)">(aa)</span> [1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(II)(bb)">(bb)</span> A-834735;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(III)">(III)</span> AB-034 (also known as [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(IV)">(IV)</span> UR-144 (also known as 1-pentyl-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(V)">(V)</span> 5-bromo-UR-144, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(V)(aa)">(aa)</span> ​[1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(V)(bb)">(bb)</span> UR-144 N-(5-bromopentyl) analog;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(VI)">(VI)</span> 5-chloro-UR-144, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(VI)(aa)">(aa)</span> 1-(5-chloropentyl)-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(VI)(bb)">(bb)</span> 5Cl-UR-144;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(VII)">(VII)</span> XLR11, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(VII)(aa)">(aa)</span> 1-(5-fluoropentyl)-3-(2,2,3, 3-tetramethylcyclopropoyl)indole;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(VII)(bb)">(bb)</span> 5-FUR-144; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(vii)(VII)(cc)">(cc)</span> 5-fluoro UR-144; and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(vii)(VIII)">(VIII)</span> FUB-144 (also known as [1-(4-Fluorobenzyl)-lH-indol-3-yl](2,2,3 ,3-tetramethylcyclopropyl)methanone);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(viii)">(viii)</span> Hexahydrodibenzopyrans: Any compound containing or structurally derived from Hexahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, except where contained in cannabis or cannabis resin;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(ix)">(ix)</span> Indazole Ester (also known as Carboxylate indazole): Any compound containing or structurally derived from 3-carboxylate-indazoles, whether or not substituted in the indazole ring to any extent or substituted to any degree on the carboxylate, whether or not substituted to any extent in the indazole ring or on the carboxylate oxygen. Examples of indazole esters include 5-fluoro SDB-005, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(ix)(I)">(I)</span> naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate; or</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(ix)(II)">(II)</span> 5F SDB-005;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(x)">(x)</span> Indole Amides: Any compound containing or structurally derived from or containing a 1H-Indole-3-carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole amides include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(I)">(I)</span> Adamantylamidoindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide structure, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(II)">(II)</span> Adamantylindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the adamantyl ring to any extent;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(III)">(III)</span> 5F ABICA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(III)(aa)">(aa)</span> (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(III)(bb)">(bb)</span> N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(III)(cc)">(cc)</span> 5-fluoro ABICA;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(IV)">(IV)</span> ADBICA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide));</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(V)">(V)</span> 5F-ADBICA, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(V)(aa)">(aa)</span> N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(V)(bb)">(bb)</span> 5-fluoro-ADBICA;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(VI)">(VI)</span> NNE1 (also known as N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(VII)">(VII)</span> 5F-NNE1, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(VII)(aa)">(aa)</span> 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide); or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(VII)(bb)">(bb)</span> 5-fluoro-NNE1;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(VIII)">(VIII)</span> SDB-006 (also known as N-benzyl-1-pentyl-1H- indole-3-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(IX)">(IX)</span> 5F-SDB-006, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(IX)(aa)">(aa)</span> N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide); or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(IX)(bb)">(bb)</span> 5-fluoro-SDB-006;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(X)">(X)</span> 2NE 1, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(X)(aa)">(aa)</span> APICA;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(X)(bb)">(bb)</span> JWH 018 adamantyl carboxamide; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(X)(cc)">(cc)</span> 1-pentyl-N-tricyclo[3.3. l .13, 7]dec-1-yl-1H-indole-3-carboxamide;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(XI)">(XI)</span> STS-135, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(XI)(aa)">(aa)</span> 1-(5-fluoropentyl)-N-tricyclo[3.3. l. l 3, 7]dec-1-yl-l H-indole-3-carboxamide;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(XI)(bb)">(bb)</span> N-adamantyl-l-fluoropentylindole-3-Carboxamide;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(XI)(cc)">(cc)</span> 5F-APICA; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(x)(XI)(dd)">(dd)</span> 5-fluoro-APICA;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(XII)">(XII)</span> SDB-006 (also known as N-benzyl-1-pentyl-lH-indole-3-carboxamide); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(x)(XIII)">(XIII)</span> 5-fluoro-MDMB-PICA (also known as N-[[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xi)">(xi)</span> Indole Esters: Any compound containing or structurally derived from a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole esters may also be referred to as Quinolinylindolecarboxylates. Indole esters include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xi)(I)">(I)</span> Quinolinyl ester indoles, or any compound containing or structurally derived from Quinolinyl ester indoles, being any compound containing or structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xi)(II)">(II)</span> BB-22, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(II)(aa)">(aa)</span> 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(II)(bb)">(bb)</span> quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(II)(cc)">(cc)</span> QUCHIC;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xi)(III)">(III)</span> FDU-PB-22 (also known as naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xi)(IV)">(IV)</span> FUB-PB-22, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(IV)(aa)">(aa)</span> 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylic acid, 8-quinolinyl ester; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(IV)(bb)">(bb)</span> Quinolin-8-yl 1-(4-fluorobenzyl)-1<em>H</em>-indole-3-carboxylate;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xi)(V)">(V)</span> NM2201, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(V)(aa)">(aa)</span> naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(V)(bb)">(bb)</span> CBL-2201;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xi)(VI)">(VI)</span> PB-22, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VI)(aa)">(aa)</span> 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VI)(bb)">(bb)</span> quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VI)(cc)">(cc)</span> 8-Quinolinyl 1-pentyl-1H-indole-3-carboxylate; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VI)(dd)">(dd)</span> "QUPIC"; and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xi)(VII)">(VII)</span> 5F-PB-22, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VII)(aa)">(aa)</span> 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VII)(bb)">(bb)</span> quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VII)(cc)">(cc)</span> 8-Quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VII)(dd)">(dd)</span> 5-fluoro-PB-22; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xi)(VII)(ee)">(ee)</span> 5-fluoro QUPIC;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xii)">(xii)</span> Naphthoylindoles: Any compound containing or structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55-212. Napthoylindoles also include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xii)(I)">(I)</span> AM-2201 (also known as (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xii)(II)">(II)</span> WIN 55,212-2, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xii)(II)(aa)">(aa)</span> (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xii)(II)(bb)">(bb)</span> [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xiii)">(xiii)</span> Naphthoylnaphthalenes: Any compound containing or structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent. Naphthoylnaphthalenes include CB-13 (also known as CRA-13 or 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xiv)">(xiv)</span> Naphthoylpyrroles: Any compound containing or structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xv)">(xv)</span> Naphthylamidoindoles: Any compound containing or structurally derived from a N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted to any extent in the indole ring or in the naphthyl ring;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xvi)">(xvi)</span> Naphthylmethyl Indoles: Any compound containing orstructurally derived from 1H-indol-3-yl-(1-naphthyl)methane structure, also known as napthylmethylindoles, with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2- (4-morpholinyl)ethyl group, or 1-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent. Examples of this structural class include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(I)">(I)</span> JWH-175 (also known as 3-(1-naphthalenylmethyl)-1-pentyl-1 H-indole );</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(II)">(II)</span> JWH-184 (also known as 3-[(4-methyl-1-naphthalenyl)methyl)-1-pentyl-l H-indole);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(III)">(III)</span> JWH-185 (also known as 3-[(4-methoxy-1-naphthalenyl)methyl]-1 -pentyl-1 H-indole);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(IV)">(IV)</span> JWH-192 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethane);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(V)">(V)</span> JWH-194 (also known as 2-methyl-1-pentyl-lH-indol-3-yl-( 4-methyl-1-naphthyl)methane);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(VI)">(VI)</span> JWH-195 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethane);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(VII)">(VII)</span> JWH-196 (also known as 2-methyl-3-(1-naphthalenylmethyl)-1-pentyl-lH-Indole);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(VIII)">(VIII)</span> JWH-197 (also known as 2-methyl-l-pentyl-lH-indol-3-yl-( 4-methoxy-1-naphthyl)methane); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvi)(IX)">(IX)</span> JWH-199 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethane);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xvii)">(xvii)</span> Naphthylmethylindenes: Any compound containing or structurally derived from a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-( 4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvii)(I)">(I)</span> JWH-171;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvii)(II)">(II)</span> JWH-176 (also known as 1-[(E)-(3-pentyl-1 H-inden-1-ylidene)methyl]-naphthalene); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xvii)(III)">(III)</span> JWH-220;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xviii)">(xviii)</span> Phenylacetylindoles: Any compound containing or structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including: JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, SR-18, and Cannabipiperidiethanone (also known as 2-(2-methoxyphenyl)-1-[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-ethanone);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xix)">(xix)</span> Quinolinoyl pyrazole: Any compound containing or structurally derived from Quinolinoyl pyrazole carboxylate (also known as Quinolinyl fluoropentyl fluorophenyl pyrazole carboxylate);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xx)">(xx)</span> Tetrahydrobenzochromen: Any compound containing or structurally derived from (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Includes tetrahydrodibenzopyrans, or any compound containing or structurally derived from tetrahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, but does not include tetrahydrodibenzopyrans that are contained in cannabis or cannabis resin. Examples of this structural class include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(I)">(I)</span> AM-087 (also known as (6aR,10aR)-3-(2-methyl-6-bromohex-2-yl)- 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(II)">(II)</span> AM-411 (also known as (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(III)">(III)</span> HU-210, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(III)(aa)">(aa)</span> 3-(1,1'-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(III)(bb)">(bb)</span> [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(III)(cc)">(cc)</span> 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(III)(dd)">(dd)</span> 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(IV)">(IV)</span> HU-211, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(IV)(aa)">(aa)</span> 3-(1,1-dimethylheptyl)-6aS,7,10,10aS-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(IV)(bb)">(bb)</span> (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(IV)(cc)">(cc)</span> (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(IV)(dd)">(dd)</span> "Dexanabinol";</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(V)">(V)</span> HU-243, also known as</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(V)(aa)">(aa)</span> (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol; or</p>
                <p class="text-indent-6"><span class="level-num" id="(6)(A)(xx)(V)(bb)">(bb)</span> 3-dimethylheptyl-11-hydroxyhexahydrocannabinol;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(VI)">(VI)</span> JWH-051 (also known as (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(VII)">(VII)</span> JWH-133 (also known as (6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xx)(VIII)">(VIII)</span> JWH-359 (also known as (6aR,10aR)- 1-methoxy-6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xxi)">(xxi)</span> Δ8 Tetrahydrocannabinol: Any compound containing or structurally derived from 11-hydroxy-Δ8-tetrahydrocannabinol structure, also known as dibenzopyrans, with further substitution on the 3-pentyl group by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkyethyl, 1-(n-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xxii)">(xxii)</span> Tetramethylcyclopropane-thiazole carboxamides: Any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2- (4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent, including the group Tetramethylcyclopropyl thiazoles, or any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent. Tetramethylcyclopropane-thiazole carboxamides also include A-836,339, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxii)(I)">(I)</span> [N(Z)]-N-[3-(2-methoxyethyl)-4,5-dimethyl-2(3H)-thiazolylidene]-2,2,3,3-tetramethyl-cyclopropanecarboxamide;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxii)(II)">(II)</span> N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropanecarboxamide: and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxii)(III)">(III)</span> A-836339;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xxiii)">(xxiii)</span> Benzodihydropyrans: Any compound containing or structurally derived from benzodihydropyrans, by substitution on the benzyl ring by hydroxy, alkyl, haloalkyl, alkoxy, cycloalkyl, alkene, haloalkene, cycloalkane, or by substitution on the pyran ring by alkyl, cycloalkyl, cycloalkene, or cycloalkoxy group to any extent. Examples of this structural class include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxiii)(I)">(I)</span> AM-855 (also known as (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9, 10,11,12b-octahydronaphtho[3,2-c]isochromen-l 2-ol);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxiii)(II)">(II)</span> AM-905 (also known as (6aR,9R, l0aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a, 7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxiii)(III)">(III)</span> AM-906 (also known as (6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a, 7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxiii)(IV)">(IV)</span> AM-2389 (also known as (6aR,9R,10aR)-3-(l-hexylcyclobut-l-yl)-6a, 7,8,9,10,1Oa-hexahydro-6,6-dimethyl-6H-dibenzo[b,d)pyran-1,9 diol);and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxiii)(V)">(V)</span> JWH-057 (also known as (6aR,10aR)-3-(1,l-dimethylheptyl)-6a, 7, 10, 10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran); and</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(A)(xxiv)">(xxiv)</span> Benzimidazole Ketone: Any compound containing or structurally derived from [IH-indazol-3-yl](l-naphthyl)methanone structure with or without substitution at either nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, l-(N-methyl-2-pyrrolidinyl)methyl, l-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, l-amino-3-methyl-1-oxobutan-2-yl, l-amino-3, 3-dimethyl-1-oxobutan-2-yl, l-methoxy-3-methyl-1-oxobutan-2-yl, l-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples of this structural class include:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxiv)(I)">(I)</span> THJ-2201 (also known as [l-(5-Fluoropentyl)-lH-indazol-3-yl](l-naphthyl)methanone); and</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(A)(xxiv)(II)">(II)</span> THJ-018 (also known as l-naphthalenyl(l-pentyl-IH-indazol-3-yl)-methanone);</p>
                <p class="text-indent-3"><span class="level-num" id="(6)(B)">(B)</span> Unclassified Synthetic Cannabimimetic Agents:</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(i)">(i)</span> AM-356, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(i)(I)">(I)</span> AM356;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(i)(II)">(II)</span> arachidonyl-1'-hydroxy-2'-propylamide;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(i)(III)">(III)</span> N-(2-hydroxy-1R-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(i)(IV)">(IV)</span> (R)-(+)-Arachidonyl-1'-Hydroxy-2'-Propylamide;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(i)(V)">(V)</span> Methanandamide; or</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(i)(VI)">(VI)</span> R-1 Methanandamide;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(ii)">(ii)</span> BAY38-7271 (also known as (-)-(R)-3-(2-Hydroxymethylindanyl -4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(iii)">(iii)</span> CP 50,556-1, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(iii)(I)">(I)</span> 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6, 6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(iii)(II)">(II)</span> [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5- phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-; octahydrophenanthridin-1-yl] acetate;</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(iii)(III)">(III)</span> [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; or</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(iii)(IV)">(IV)</span> "Levonantradol";</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(iv)">(iv)</span> HU-308 (also known as (91R,2R,5R)-2-[2,6-dimethoxy-4- (2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(v)">(v)</span> HU-331 (also known as 3-hydroxy-2-[(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(vi)">(vi)</span> JTE-907 (also known as N-(benzol[1,3]dioxol-5-ylmethyl) –7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(vii)">(vii)</span> Mepirapim (also known as (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) Methanone);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(viii)">(viii)</span> URB597 (also known as [3-(3-carbamoylphenyl)phenyl] –N-Cyclohexylcarbamate);</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(ix)">(ix)</span> URB602, also known as:</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(ix)(I)">(I)</span> [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or</p>
                <p class="text-indent-5"><span class="level-num" id="(6)(B)(ix)(II)">(II)</span> cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(x)">(x)</span> URB754 (also known as 6-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one); and</p>
                <p class="text-indent-4"><span class="level-num" id="(6)(B)(xi)">(xi)</span> URB937 (also known as 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl Cyclohexylcarbamate).</p>
                <p class="text-indent-2"><span class="level-num" id="(7)">(7)</span> Synthetic opioids, which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, their salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(7)(A)">(A)</span> Classified Synthetic Opioids:</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(A)(i)">(i)</span> Fentanyls: Any compound, other than carbomethoxyfentanyls, containing or structurally derived from N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide, whether or not substituted on the methanone group with an alkyl, alkene, halo, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, cyanoalkyl, hydroxyalkyl, furanyl, or alkoxy, and whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Examples of fentanyls include:</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(i)(I)">(I)</span> Fentanyl (also known as N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(i)(II)">(II)</span> Furanylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(i)(III)">(III)</span> Acetylfentanyl (also known as N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(i)(IV)">(IV)</span> Acrylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]prop-2-enamide);</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(i)(V)">(V)</span> Parafluorofentanyl, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(V)(aa)">(aa)</span> 4-fluorofentanyl; or</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(V)(bb)">(bb)</span> N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide;</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(i)(VI)">(VI)</span> Butyryl fentanyl, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VI)(aa)">(aa)</span> Butyr fentanyl;</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VI)(bb)">(bb)</span> NIH 10486; or</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VI)(cc)">(cc)</span> N-phenyl-N-[l-(2-phenylethyl)-4-piperidinyl]-butanamide; and</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(i)(VII)">(VII)</span> para-Fluorobutyryl fentanyl, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VII)(aa)">(aa)</span> 4-FPF;</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VII)(bb)">(bb)</span> p-FBF;</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VII)(cc)">(cc)</span> 4-Fluorobutyryl fentanyl;</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VII)(dd)">(dd)</span> p-Fluorobutyryl fentanyl; or</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(i)(VII)(ee)">(ee)</span> N-( 4-fluorophenyl)-N-[ l -(2-phenylethyl)-4-piperidinyl]-butanamide);</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(A)(ii)">(ii)</span> Carbomethoxyfentanyls: Any compound containing or structurally derived from 4-((1-oxopropyl)-phenylamino )-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester, whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Carbomethoxyfentanyls include:</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(ii)(I)">(I)</span> Carfentanil, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(ii)(I)(aa)">(aa)</span> 4-Carbomethoxy Fentanyl;</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(ii)(I)(bb)">(bb)</span> 4-carbomethoxy Fentanyl; or</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(ii)(I)(cc)">(cc)</span> 4-[(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylic acid, methyl ester;</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(ii)(II)">(II)</span> Norcarfentanil (also known as: 4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester; and</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(ii)(III)">(III)</span> N-methyl Norcarfentanil, also known as:</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(ii)(III)(aa)">(aa)</span> N-methyl Carfentanil;</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(ii)(III)(bb)">(bb)</span> N-methyl Norremifentanil;</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(ii)(III)(cc)">(cc)</span> N-methyl Remifentanil; or</p>
                <p class="text-indent-6"><span class="level-num" id="(7)(A)(ii)(III)(dd)">(dd)</span> 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester; and</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(A)(iii)">(iii)</span> Benzamides: Any compound containing or structurally derived from 3,4-Dichloro-N-[(1 R,2R)-2-(dimethylamino )cyclohexyl]-N-methylbenzamide, whether or not substituted on the phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group, and whether or not substituted with an alkyl or hydrogen on the nitrogen of the amide, and whether or not substituted on the nitrogen of the amide with an alkyl, cycloalkyl, tertiary amine, or combination thereof. Benzamides include:</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(iii)(I)">(I)</span> U-47700 (also known as 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide); and</p>
                <p class="text-indent-5"><span class="level-num" id="(7)(A)(iii)(II)">(II)</span> AH-7921 (also known as 3,4-dichloro-N-[[l-(dimethylamino)cyclohexyl]methyl]benzamide).</p>
                <p class="text-indent-3"><span class="level-num" id="(7)(B)">(B)</span> Unclassified Synthetic Opioids:</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(B)(i)">(i)</span> W-18 (also known as 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide);</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(B)(ii)">(ii)</span> Sufentanil (also known as N-[4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide);</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(B)(iii)">(iii)</span> Alfentanil (also known as N-[1-[2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-N-phenyl-propanamide);</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(B)(iv)">(iv)</span> Remifentanil (also known as 4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid, methyl ester);</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(B)(v)">(v)</span> Lofentanil (also known as methyl (3R,4S)-3-methyl-1-(2-phenylethyl)-4-(N-propanoylanilino)piperidine-4-carboxylate);</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(B)(vi)">(vi)</span> Benzyl Carfentanil (also known as methyl 1-benzyl-4-(N-phenylpropionamido)piperidine-4-carboxylate); and</p>
                <p class="text-indent-4"><span class="level-num" id="(7)(B)(vii)">(vii)</span> N-methyl-Norcarfentanil (also known as 1-methyl-4-[(1-oxopropyl)phenylamino]-4-piperidinecarboxylic acid, methyl ester).</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§204" title="§ 204.">Aug. 5, 1981, D.C. Law 4-29, § 204, 28 DCR 3081</a>; amended by rule, 39 DCR 1882; amended by rule, Dec. 7, 1994, 41 DCR 7967; <a class="internal-link" href="/dc/council/laws/13-99.html" title="D.C. Law 13-99. Uniform Controlled Substances Amendment Act of 1999.">May 9, 2000, D.C. Law 13-99, § 2(a), 47 DCR 791</a>; <a class="internal-link" href="/dc/council/laws/18-88.html" title="D.C. Law 18-88. Omnibus Public Safety and Justice Amendment Act of 2009.">Dec. 10, 2009, D.C. Law 18-88, § 225, 56 DCR 7413</a>; <a class="internal-link" href="/dc/council/laws/19-320.html" title="D.C. Law 19-320. Omnibus Criminal Code Amendments Act of 2012.">June 19, 2013, D.C. Law 19-320, § 301(b), 60 DCR 3390</a>; <a class="internal-link" href="/dc/council/laws/22-243.html#§2(b)" title="">Mar. 13, 2019, D.C. Law 22-243, § 2(b), 66 DCR 937</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-514.</p>
                <h4>Section References</h4>
                <p>This section is referenced in <a class="internal-link no-wrap" href="/dc/council/code/sections/7-3002.html">§ 7-3002</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/44-1201.html">§ 44-1201</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-901.02.html">§ 48-901.02</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.02.html">§ 48-902.02</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-1004.html">§ 48-1004</a>, and <a class="internal-link no-wrap" href="/dc/council/code/sections/50-2206.13.html">§ 50-2206.13</a>.</p>
                <h4>Effect of Amendments</h4>
                <p><a class="internal-link " href="/dc/council/laws/13-99.html">D.C. Law 13-99</a> corrected the way in which two chemicals were stated in subsec. (3) and added provisions contained in (X) and (Y) in subsec. (3).</p>
                <p><a class="internal-link " href="/dc/council/laws/18-88.html">D.C. Law 18-88</a>, in par. (5), deleted “and” from the end of subpar. (A), substituted “; and” for a period at the end of subpar. (B), and added subpar. (C).</p>
                <p>The 2013 amendment by <a class="internal-link " href="/dc/council/laws/19-320.html">D.C. Law 19-320</a> added (3)(Z) through (3)(KK); added (4)(C); inserted “their analogues or derivatives and” in the introductory language of (5); added (5)(D) through (5)(H); and made related changes.</p>
                <h4>Emergency Legislation</h4>
                <p>
                  <a class="internal-link" href="/dc/council/acts/22-550.html#§2(b)" title="">For temporary (90 days) amendment of this section, see <a class="internal-link " href="/dc/council/acts/22-550.html#§2(b)">§ 2(b) of Revised Synthetics Abatement and Full Enforcement Drug Control Congressional Review Emergency Amendment Act of 2018 (D.C. Act 22-550, Dec. 26, 2018, 66 DCR 225)</a>.</a>
                </p>
                <p>
                  <a class="internal-link" href="/dc/council/acts/22-464.html#§2(b)" title="">For temporary (90 days) amendment of this section, see <a class="internal-link " href="/dc/council/acts/22-464.html#§2(b)">§ 2(b) of Revised Synthetics Abatement and Full Enforcement Drug Control Emergency Amendment Act of 2018 (D.C. Act 22-464, Oct. 5, 2018, 65 DCR 11377)</a>.</a>
                </p>
                <p>For temporary (90-day) amendment of section, see § 2 of the Uniform Controlled Substances Emergency Amendment Act of 1999 (D.C. Act 13-96, June 15, 1999,  46 DCR 5640).</p>
                <p>For temporary (90-day) amendment of section, see § 2 of the Uniform Controlled Substances Congressional Review Emergency Amendment Act of 1999 (D.C. Act 13-144, October 18, 1999,  46 DCR 9904).</p>
                <p>For temporary (90 day) amendment of section, see § 225 of Omnibus Public Safety and Justice Emergency Amendment Act of 2009 (D.C. Act 18-181, August 6, 2009,  56 DCR 6903).</p>
                <p>For temporary (90 day) amendment of section, see § 225 of Omnibus Public Safety and Justice Congressional Review Emergency Amendment Act of 2009 (D.C. Act 18-227, October 21, 2009,  56 DCR 8668).</p>
                <p>For temporary amendment of section, see § 301(b) of the Omnibus Public Safety and Justice Amendment Act of 2012 (D.C. Act 19-599, January 14, 2013,  60 DCR 1017).</p>
                <p>For temporary (90 days) amendment of this section, see § 301(b) of the Omnibus Criminal Code Amendment Congressional Review Emergency Act of 2013 (D.C. Act 20-44, April 1, 2013,  60 DCR 5381, 20 DCSTAT 1281).</p>
                <h4>Temporary Legislation</h4>
                <p>
                  <a class="internal-link" href="/dc/council/laws/22-204.html#§2(b)" title="">For temporary (225 days) amendment of this section, see <a class="internal-link " href="/dc/council/laws/22-204.html#§2(b)">§ 2(b) of Revised Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2018 (D.C. Law 22-204, Feb. 22, 2019, 65 DCR 12338)</a>.</a>
                </p>
                <p>
                  <a class="internal-link" href="/dc/council/laws/21-131.html#§2(b)" title="">For temporary (225 days) amendment of this section, see <a class="internal-link " href="/dc/council/laws/21-131.html#§2(b)">§ 2(b) of Revised Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2016 (D.C. Law 21-131, July 1, 2016, 63 DCR 7110)</a>.</a>
                </p>
                <p>For temporary (225 day) amendment of section, see § 2 of Uniform Controlled Substances Temporary Amendment Act of 1999 (D.C. Law 13-34, October 7, 1999, law notification  47 DCR 3423).</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.05. Schedule II tests.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The Mayor shall place a substance in Schedule II if the Mayor finds that:</p>
                <p class="text-indent-1"><span class="level-num" id="(1)">(1)</span> The substance has high potential for abuse;</p>
                <p class="text-indent-1"><span class="level-num" id="(2)">(2)</span> The substance has currently accepted medical use in treatment in the United States or the District of Columbia, or currently accepted medical use, with severe restrictions; and</p>
                <p class="text-indent-1"><span class="level-num" id="(3)">(3)</span> The abuse of the substance may lead to severe psychological or physical dependence.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§205" title="§ 205.">Aug. 5, 1981, D.C. Law 4-29, § 205, 28 DCR 3081</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-515.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.06. Schedule II enumerated.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The controlled substances listed in this section are included in Schedule II unless and until removed therefrom pursuant to <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>:</p>
                <p class="text-indent-1"><span class="level-num" id="(1)">(1)</span> Unless specifically excepted or unless listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(A)">(A)</span> Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, naloxone, naltrexone, and their respective salts, but including the following:</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(i)">(i)</span> Raw opium;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(ii)">(ii)</span> Opium extracts;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(iii)">(iii)</span> Opium fluid extracts;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(iv)">(iv)</span> Powdered opium;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(v)">(v)</span> Granulated opium;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(vi)">(vi)</span> Tincture of opium;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(vii)">(vii)</span> Codeine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(viii)">(viii)</span> Ethylmorphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(ix)">(ix)</span> Etorphine Hydrochloride;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(x)">(x)</span> Hydrocodone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xi)">(xi)</span> Metopon;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xii)">(xii)</span> Morphine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xiii)">(xiii)</span> Oxycodone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xiv)">(xiv)</span> Oxymorphone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xv)">(xv)</span> Thebaine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xvi)">(xvi)</span> Hydromorphone;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xvii)">(xvii)</span> Dihydrocodeine;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xviii)">(xviii)</span> Sufentanil;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xix)">(xix)</span> Alfentanil; and</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(A)(xx)">(xx)</span> Carfentanil;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(B)">(B)</span> Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in subparagraph (A) of this paragraph, but not including the isoquinoline alkaloids of opium;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(C)">(C)</span> Opium poppy and poppy straw;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(D)">(D)</span> Coca leaves, except coca leaves or extracts of coca leaves from which cocaine, ecgonine, or derivatives of ecgonine or their salts have been removed; cocaine, its salts, optical and geometric isomers, and salts of isomers; or any compound, mixture, or preparation that contains any substance referred to in this paragraph;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(E)">(E)</span> Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy);</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(F)">(F)</span> Hashish; and</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(G)">(G)</span> Synthetic Tetrahydrocannabinols: Chemical equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, and synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following:</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(G)(i)">(i)</span> Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers;</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(G)(ii)">(ii)</span> Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; or</p>
                <p class="text-indent-3"><span class="level-num" id="(1)(G)(iii)">(iii)</span> Delta 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers (compounds of these structures, regardless of numerical designation of atomic positions covered);</p>
                <p class="text-indent-1"><span class="level-num" id="(2)">(2)</span> Unless specifically excepted or unless in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan excepted:</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(A)">(A)</span> Alphaprodine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(B)">(B)</span> Anileridine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(C)">(C)</span> Bezitramide;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(D)">(D)</span> Biphetamine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(E)">(E)</span> Diphenoxylate;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(F)">(F)</span> Eskatrol;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(G)">(G)</span> Fentanyl;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(H)">(H)</span> Fetamine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(I)">(I)</span> Isomethadone;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(J)">(J)</span> Levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(K)">(K)</span> Levomethorphan;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(L)">(L)</span> Levorphanol;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(M)">(M)</span> Metazocine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(N)">(N)</span> Methadone;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(O)">(O)</span> Methadone—Intermediate, 4-cyano-2-dimethylamino4, 4-diphenyl butane;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(P)">(P)</span> Moramide—Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl- propane-carboxylic acid;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(Q)">(Q)</span> Pethidine (meperidine);</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(R)">(R)</span> Pethidine—Intermediate — A, 4-cyano-1-methyl-4- phenylpiperidine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(S)">(S)</span> Pethidine—Intermediate — B, ethyl-4-phenylpiperidine- 4-carboxylate;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(T)">(T)</span> Pethidine—Intermediate — C, 1-methyl-4-phenylpiperdine- 4-carboxylic acid;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(U)">(U)</span> Phenazocine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(V)">(V)</span> Piminodine;</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(W)">(W)</span> Racemethorphan; and</p>
                <p class="text-indent-2"><span class="level-num" id="(2)(X)">(X)</span> Racemorphan;</p>
                <p class="text-indent-1"><span class="level-num" id="(3)">(3)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:</p>
                <p class="text-indent-2"><span class="level-num" id="(3)(A)">(A)</span> Amphetamine, its salts, optical isomers, and salts of its optical isomers;</p>
                <p class="text-indent-2"><span class="level-num" id="(3)(B)">(B)</span> Methamphetamine, its salts, isomers, and salts of its isomers;</p>
                <p class="text-indent-2"><span class="level-num" id="(3)(C)">(C)</span> Phenmetrazine and its salts;</p>
                <p class="text-indent-2"><span class="level-num" id="(3)(D)">(D)</span> Methylphenidate and its salts;</p>
                <p class="text-indent-2"><span class="level-num" id="(3)(E)">(E)</span> Repealed.</p>
                <p class="text-indent-2"><span class="level-num" id="(3)(F)">(F)</span> Amphetamine/methamphetamine immediate precursor: Phenyl acetone (Phenyl-2-propanone), P2P; and</p>
                <p class="text-indent-1"><span class="level-num" id="(4)">(4)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(A)">(A)</span> Methagualone;</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(B)">(B)</span> Amobarbital;</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(C)">(C)</span> Secobarbital;</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(D)">(D)</span> Pentobarbital;</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(E)">(E)</span> Phencyclidine;</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(F)">(F)</span> Phencyclidine immediate precursors:</p>
                <p class="text-indent-3"><span class="level-num" id="(4)(F)(i)">(i)</span> 1-phenyleyclohexylamine</p>
                <p class="text-indent-3"><span class="level-num" id="(4)(F)(ii)">(ii)</span> 1-piperidinocyclohexanecarbonitrile (PCC);</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(G)">(G)</span> Dronabinol;</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(H)">(H)</span> Nabilone; and</p>
                <p class="text-indent-2"><span class="level-num" id="(4)(I)">(I)</span> Glutethimide.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§206" title="§ 206.">Aug. 5, 1981, D.C. Law 4-29, § 206, 28 DCR 3081</a>; amended by rule, 32 DCR 1097; <a class="internal-link" href="/dc/council/laws/8-138.html" title="D.C. Law 8-138. Omnibus Narcotic and Abusive Drug Interdiction Amendment Act of 1990.">June 13, 1990, D.C. Law 8-138, § 2(b), 37 DCR 2638</a>; amended by rule, 39 DCR 1882; amended by rule, Dec. 7, 1994, 41 DCR 7967; <a class="internal-link" href="/dc/council/laws/19-320.html" title="D.C. Law 19-320. Omnibus Criminal Code Amendments Act of 2012.">June 19, 2013, D.C. Law 19-320, § 301(c), 60 DCR 3390</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-516.</p>
                <h4>Section References</h4>
                <p>This section is referenced in <a class="internal-link no-wrap" href="/dc/council/code/sections/7-3002.html">§ 7-3002</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/44-1201.html">§ 44-1201</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-853.01.html">§ 48-853.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-901.02.html">§ 48-901.02</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.02.html">§ 48-902.02</a>, and <a class="internal-link no-wrap" href="/dc/council/code/sections/48-1004.html">§ 48-1004</a>.</p>
                <h4>Effect of Amendments</h4>
                <p>The 2013 amendment by <a class="internal-link " href="/dc/council/laws/19-320.html">D.C. Law 19-320</a> substituted “Dronabinol” for “Dronabianol” in (4)(G).</p>
                <h4>Emergency Legislation</h4>
                <p>For temporary amendment of (4)(G), see § 301(c) of the Omnibus Criminal Code Amendments Emergency Amendment Act of 2012 (D.C. Act 19-599, January 14, 2013,  60 DCR 1017).</p>
                <p>For temporary (90 days) amendment of this section, see § 301(c) of the Omnibus Criminal Code Amendment Congressional Review Emergency Act of 2013 (D.C. Act 20-44, April 1, 2013,  60 DCR 5381, 20 DCSTAT 1281).</p>
                <h4>Editor's Notes</h4>
                <p>Mayor to implement public information program: See Historical and Statutory Notes following <a class="internal-link no-wrap" href="/dc/council/code/sections/48-901.02.html">§ 48-901.02</a>.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.07. Schedule III tests.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The Mayor shall place a substance in Schedule III if the Mayor finds that:</p>
                <p class="text-indent-1"><span class="level-num" id="(1)">(1)</span> The substance has a potential for abuse less than the substances listed in Schedules I and II;</p>
                <p class="text-indent-1"><span class="level-num" id="(2)">(2)</span> The substance has currently accepted medical use in treatment in the United States or the District of Columbia; and</p>
                <p class="text-indent-1"><span class="level-num" id="(3)">(3)</span> The abuse of the substance may lead to moderate or low physical dependence or high psychological dependence.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§207" title="§ 207.">Aug. 5, 1981, D.C. Law 4-29, § 207, 28 DCR 3081</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-517.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.08. Schedule III enumerated.</h1>
            <section>
              <section class="line-group primary-content">
                <p class="text-indent-1"><span class="level-num" id="(a)">(a)</span> The controlled substances listed in this section are included in Schedule III, unless and until removed therefrom pursuant to <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>:</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(1)">(1)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(A)">(A)</span> Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(B)">(B)</span> Benzphetamine;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(C)">(C)</span> Chlorphentermine;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(D)">(D)</span> Chlortermine;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(E)">(E)</span> Mazindol; and</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(F)">(F)</span> Phendimetrazine;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(2)">(2)</span> Unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(2)(A)">(A)</span> Any compound, mixture, or preparation containing:</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(A)(i)">(i)</span> Amobarbital;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(A)(ii)">(ii)</span> Secobarbital; or</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(A)(iii)">(iii)</span> Pentobarbital; or any salt thereof and 1 or more other active medicinal ingredients which are not listed in any schedule;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(2)(B)">(B)</span> Any suppository dosage form containing:</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(B)(i)">(i)</span> Amobarbital;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(B)(ii)">(ii)</span> Secobarbital;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(B)(iii)">(iii)</span> Pentobarbital; or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(2)(C)">(C)</span> Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid:</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(i)">(i)</span> Chlorhexadol;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(ii)">(ii)</span> Rescheduled to Schedule II;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(iii)">(iii)</span> Lysergic acid;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(iv)">(iv)</span> Lysergic acid amide;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(v)">(v)</span> Methyprylon;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(vi)">(vi)</span> Sulfondiethylmethane;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(vii)">(vii)</span> Sulfonethylmethane;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(viii)">(viii)</span> Sulfonmethane;</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(ix)">(ix)</span> Tiletamine &amp; Zolazepam Combination Product; and</p>
                <p class="text-indent-4"><span class="level-num" id="(a)(2)(C)(x)">(x)</span> Vinbarbital;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(3)">(3)</span> Nalorphine;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(4)">(4)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(A)">(A)</span> Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(B)">(B)</span> Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(C)">(C)</span> Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a 4-fold or greater quantity of an isoquinoline alkaloid of opium;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(D)">(D)</span> Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(E)">(E)</span> Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(F)">(F)</span> Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with 1 or more ingredients in recognized therapeutic amounts;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(G)">(G)</span> Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts; and</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(H)">(H)</span> Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with 1 or more active, nonnarcotic ingredients in recognized therapeutic amounts;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(5)">(5)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, drug, or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progesterons, and corticorsteroids) that promotes muscle growth and includes:</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(A)">(A)</span> Boldenone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(B)">(B)</span> Chlortestosterone (4-chlortestosterone);</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(C)">(C)</span> Clostebol;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(D)">(D)</span> Dehydrochlormethyltestosterone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(E)">(E)</span> Dihydrotestosterone (4-dihydrotestosterone);</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(F)">(F)</span> Drostanolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(G)">(G)</span> Ethylestrenol;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(H)">(H)</span> Fluoxymestorone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(I)">(I)</span> Formebulone (formebolone);</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(J)">(J)</span> Mesterolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(K)">(K)</span> Methandienone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(L)">(L)</span> Methandranone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(M)">(M)</span> Methandriol;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(N)">(N)</span> Methandrostenolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(O)">(O)</span> Methenolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(P)">(P)</span> Methyltestosterone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(Q)">(Q)</span> Mibolerone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(R)">(R)</span> Nandrolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(S)">(S)</span> Norethandrolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(T)">(T)</span> Oxandrolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(U)">(U)</span> Oxymesterone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(V)">(V)</span> Oxymetholone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(W)">(W)</span> Stanolone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(X)">(X)</span> Stanozolol;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(Y)">(Y)</span> Testolactone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(Z)">(Z)</span> Testosterone;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(AA)">(AA)</span> Trenbolone; and</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(5)(BB)">(BB)</span> Any salt, ester or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by Secretary of Health and Human Services for such administration. If any person prescribes, dispenses or distributes such steroid for human use such person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of this paragraph; and</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(6)">(6)</span> Cannabis.</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(7)">(7)</span> Repealed.</p>
                <p class="text-indent-1"><span class="level-num" id="(b)">(b)</span> The Mayor may except by rule any compound, mixture, or preparation containing any stimulant or depressant substance listed in paragraphs (1) and (2) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains 1 or more active medicinal ingredients not having a stimulant or depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a stimulant or depressant effect on the central nervous system.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§208" title="§ 208.">Aug. 5, 1981, D.C. Law 4-29, § 208, 28 DCR 3081</a>; amended by rule, 39 DCR 1882; amended by rule Dec. 7, 1994, 41 DCR 7967; <a class="internal-link" href="/dc/council/laws/13-300.html" title="D.C. Law 13-300. Distribution of Marijuana Amendment Act of 2000.">June 8, 2001, D.C. Law 13-300, § 2(a), 47 DCR 7037</a>; <a class="internal-link" href="/dc/council/laws/19-320.html" title="D.C. Law 19-320. Omnibus Criminal Code Amendments Act of 2012.">June 19, 2013, D.C. Law 19-320, § 301(d), 60 DCR 3390</a>; <a class="internal-link" href="/dc/council/laws/22-243.html#§2(c)" title="">Mar. 13, 2019, D.C. Law 22-243, § 2(c), 66 DCR 937</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-518.</p>
                <h4>Section References</h4>
                <p>This section is referenced in <a class="internal-link no-wrap" href="/dc/council/code/sections/7-3002.html">§ 7-3002</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/44-1201.html">§ 44-1201</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-853.01.html">§ 48-853.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.02.html">§ 48-902.02</a>, and <a class="internal-link no-wrap" href="/dc/council/code/sections/48-1004.html">§ 48-1004</a>.</p>
                <h4>Effect of Amendments</h4>
                <p><a class="internal-link " href="/dc/council/laws/13-300.html">D.C. Law 13-300</a>, in subsec. (a), deleted “and” at the end of par. (4)(H), substituted “; and” for the period at the end of par. (5)(BB), and added par. (6).</p>
                <p>The 2013 amendment by <a class="internal-link " href="/dc/council/laws/19-320.html">D.C. Law 19-320</a> added (a)(7); and made related changes.</p>
                <h4>Emergency Legislation</h4>
                <p>
                  <a class="internal-link" href="/dc/council/acts/22-550.html#§2(c)" title="">For temporary (90 days) amendment of this section, see <a class="internal-link " href="/dc/council/acts/22-550.html#§2(c)">§ 2(c) of Revised Synthetics Abatement and Full Enforcement Drug Control Congressional Review Emergency Amendment Act of 2018 (D.C. Act 22-550, Dec. 26, 2018, 66 DCR 225)</a>.</a>
                </p>
                <p>
                  <a class="internal-link" href="/dc/council/acts/22-464.html#§2(c)" title="">For temporary (90 days) amendment of this section, see <a class="internal-link " href="/dc/council/acts/22-464.html#§2(c)">§ 2(c) of Revised Synthetics Abatement and Full Enforcement Drug Control Emergency Amendment Act of 2018 (D.C. Act 22-464, Oct. 5, 2018, 65 DCR 11377)</a>.</a>
                </p>
                <p>For temporary amendment of (a), see § 301(d) of the Omnibus Criminal Code Amendments Emergency Amendment Act of 2012 (D.C. Act 19-599, January 14, 2013,  60 DCR 1017).</p>
                <p>For temporary (90 days) amendment of this section, see § 301(d) of the Omnibus Criminal Code Amendment Congressional Review Emergency Act of 2013 (D.C. Act 20-44, April 1, 2013,  60 DCR 5381, 20 DCSTAT 1281).</p>
                <h4>Temporary Legislation</h4>
                <p>
                  <a class="internal-link" href="/dc/council/laws/22-204.html#§2(c)" title="">For temporary (225 days) amendment of this section, see <a class="internal-link " href="/dc/council/laws/22-204.html#§2(c)">§ 2(c) of Revised Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2018 (D.C. Law 22-204, Feb. 22, 2019, 65 DCR 12338)</a>.</a>
                </p>
                <p>
                  <a class="internal-link" href="/dc/council/laws/21-131.html#§2(c)" title="">For temporary (225 days) amendment of this section, see <a class="internal-link " href="/dc/council/laws/21-131.html#§2(c)">§ 2(c) of Revised Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2016 (D.C. Law 21-131, July 1, 2016, 63 DCR 7110)</a>.</a>
                </p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.09. Schedule IV tests.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The Mayor shall place a substance in Schedule IV if the Mayor finds that:</p>
                <p class="text-indent-1"><span class="level-num" id="(1)">(1)</span> The substance has a low potential for abuse relative to substances in Schedule III;</p>
                <p class="text-indent-1"><span class="level-num" id="(2)">(2)</span> The substance has currently accepted medical use in treatment in the United States or the District of Columbia; and</p>
                <p class="text-indent-1"><span class="level-num" id="(3)">(3)</span> The abuse of the substance may lead to limited physical dependence or psychological dependence relative to the substances in Schedule III.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§209" title="§ 209.">Aug. 5, 1981, D.C. Law 4-29, § 209, 28 DCR 3081</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-519.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.10. Schedule IV enumerated.</h1>
            <section>
              <section class="line-group primary-content">
                <p class="text-indent-1"><span class="level-num" id="(a)">(a)</span> The controlled substances listed in this section are included in Schedule IV, unless and until removed therefrom pursuant to <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>:</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(1)">(1)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(A)">(A)</span> Barbital;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(B)">(B)</span> Chloral betaine;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(C)">(C)</span> Chloral hydrate;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(D)">(D)</span> Chlordiazepoxide;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(E)">(E)</span> Clonazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(F)">(F)</span> Clorazepate;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(G)">(G)</span> Dextropropoxyphene;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(H)">(H)</span> Diazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(I)">(I)</span> Ethchlorvynol;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(J)">(J)</span> Ethinamate;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(K)">(K)</span> Flurazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(L)">(L)</span> Lorazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(M)">(M)</span> Mebutamate;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(N)">(N)</span> Meprobamate;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(O)">(O)</span> Methohexital;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(P)">(P)</span> Methylphenobarbital (mephobarbital);</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(Q)">(Q)</span> Oxazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(R)">(R)</span> Paraldehyde;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(S)">(S)</span> Petrichloral;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(T)">(T)</span> Phenobarbital;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(U)">(U)</span> Prazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(V)">(V)</span> Alprazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(W)">(W)</span> Bromazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(X)">(X)</span> Camazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(Y)">(Y)</span> Clobazam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(Z)">(Z)</span> Clotiazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(AA)">(AA)</span> Cloxazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(BB)">(BB)</span> Delorazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(CC)">(CC)</span> Estazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(DD)">(DD)</span> Ethyl loflazepate;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(EE)">(EE)</span> Fludiazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(FF)">(FF)</span> Flunitrazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(GG)">(GG)</span> Halazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(HH)">(HH)</span> Haloxazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(II)">(II)</span> Ketazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(JJ)">(JJ)</span> Loprazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(KK)">(KK)</span> Lormetazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(LL)">(LL)</span> Medazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(MM)">(MM)</span> Midazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(NN)">(NN)</span> Nimetazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(OO)">(OO)</span> Nitrazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(PP)">(PP)</span> Oxazolam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(QQ)">(QQ)</span> Omitted;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(RR)">(RR)</span> Pinazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(SS)">(SS)</span> Quazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(TT)">(TT)</span> Temazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(UU)">(UU)</span> Tetrazepam;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(VV)">(VV)</span> Triazolam; and</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(1)(WW)">(WW)</span> Fospropofol;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(2)">(2)</span> Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible, such as Fenfluramine;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(3)">(3)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(A)">(A)</span> Diethylpropion;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(B)">(B)</span> Phentermine;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(C)">(C)</span> Pemoline (including organometallic complexes and chelates thereof);</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(D)">(D)</span> Cathine;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(E)">(E)</span> Fencamfimin;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(F)">(F)</span> Fenproporex;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(G)">(G)</span> Mefenorex;</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(H)">(H)</span> Pipradrol; and</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(3)(I)">(I)</span> SPA;</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(4)">(4)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(A)">(A)</span> Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1), 2-diphenyl-1-3-methyl-2-propionoxybutane; and</p>
                <p class="text-indent-3"><span class="level-num" id="(a)(4)(B)">(B)</span> Pentazocine; and</p>
                <p class="text-indent-2"><span class="level-num" id="(a)(5)">(5)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof of not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.</p>
                <p class="text-indent-1"><span class="level-num" id="(b)">(b)</span> The Mayor may except by rule any compound, mixture, or preparation containing any depressant substance listed in paragraph (1) of subsection (a) of this section from the application of all or any part of this chapter if the compound, mixture, or preparation contains 1 or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§210" title="§ 210.">Aug. 5, 1981, D.C. Law 4-29, § 210, 28 DCR 3081</a>; amended by rule, 39 DCR 1882; <a class="internal-link" href="/dc/council/laws/19-320.html" title="D.C. Law 19-320. Omnibus Criminal Code Amendments Act of 2012.">June 19, 2013, D.C. Law 19-320, § 301(e), 60 DCR 3390</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-520.</p>
                <h4>Section References</h4>
                <p>This section is referenced in <a class="internal-link no-wrap" href="/dc/council/code/sections/7-3002.html">§ 7-3002</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/44-1201.html">§ 44-1201</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-853.01.html">§ 48-853.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.02.html">§ 48-902.02</a>, and <a class="internal-link no-wrap" href="/dc/council/code/sections/48-1004.html">§ 48-1004</a>.</p>
                <h4>Effect of Amendments</h4>
                <p>The 2013 amendment by <a class="internal-link " href="/dc/council/laws/19-320.html">D.C. Law 19-320</a> added (a)(1)(WW) and made related changes; and substituted “Cathine” for “Cathine” (made no change) in (a)(3)(D).</p>
                <h4>Emergency Legislation</h4>
                <p>For temporary amendment of (a), see § 301(e) of the Omnibus Criminal Code Amendments Emergency Amendment Act of 2012 (D.C. Act 19-599, January 14, 2013,  60 DCR 1017).</p>
                <p>For temporary (90 days) amendment of this section, see § 301(e) of the Omnibus Criminal Code Amendment Congressional Review Emergency Act of 2013 (D.C. Act 20-44, April 1, 2013,  60 DCR 5381, 20 DCSTAT 1281).</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.11. Schedule V tests.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The Mayor shall place a substance in Schedule V if the Mayor finds that:</p>
                <p class="text-indent-1"><span class="level-num" id="(1)">(1)</span> The substance has low potential for abuse relative to the controlled substances listed in Schedule IV;</p>
                <p class="text-indent-1"><span class="level-num" id="(2)">(2)</span> The substance has currently accepted medical use in treatment in the United States or the District of Columbia; and</p>
                <p class="text-indent-1"><span class="level-num" id="(3)">(3)</span> The substance has limited physical dependence or psychological dependence liability relative to the controlled substances listed in Schedule IV.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§211" title="§ 211.">Aug. 5, 1981, D.C. Law 4-29, § 211, 28 DCR 3081</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-521.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.12. Schedule V enumerated.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The controlled substances listed in this section are included in Schedule V unless and until removed therefrom pursuant to <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>.</p>
                <p class="text-indent-1"><span class="level-num" id="(1)">(1)</span> Any compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or salts thereof, which also contains 1 or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(A)">(A)</span> Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(B)">(B)</span> Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(C)">(C)</span> Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(D)">(D)</span> Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(E)">(E)</span> Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit; and</p>
                <p class="text-indent-2"><span class="level-num" id="(1)(F)">(F)</span> Not more than 0.5 milligrams of difenopin and not less than 25 micrograms of atropine sulfate per dosage unit;</p>
                <p class="text-indent-1"><span class="level-num" id="(2)">(2)</span> Repealed;</p>
                <p class="text-indent-1"><span class="level-num" id="(3)">(3)</span> Deleted upon adoption of rule in 34 DCMR 4370 on July 10, 1987;</p>
                <p class="text-indent-1"><span class="level-num" id="(4)">(4)</span> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs and their salts, as set forth below:</p>
                <p>Buprenorphine;</p>
                <p class="text-indent-1"><span class="level-num" id="(5)">(5)</span> Prophylhexedrine; and</p>
                <p class="text-indent-1"><span class="level-num" id="(6)">(6)</span> Pyrovalerone.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§212" title="§ 212.">Aug. 5, 1981, D.C. Law 4-29, § 212, 28 DCR 3081</a>; amended by rule, 39 DCR 1882; <a class="internal-link" href="/dc/council/laws/13-300.html" title="D.C. Law 13-300. Distribution of Marijuana Amendment Act of 2000.">June 8, 2001, D.C. Law 13-300, § 2(b), 47 DCR 7037</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-522.</p>
                <h4>Section References</h4>
                <p>This section is referenced in <a class="internal-link no-wrap" href="/dc/council/code/sections/7-3002.html">§ 7-3002</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/44-1201.html">§ 44-1201</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-853.01.html">§ 48-853.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.01.html">§ 48-902.01</a>, <a class="internal-link no-wrap" href="/dc/council/code/sections/48-902.02.html">§ 48-902.02</a>, and <a class="internal-link no-wrap" href="/dc/council/code/sections/48-1004.html">§ 48-1004</a>.</p>
                <h4>Effect of Amendments</h4>
                <p><a class="internal-link " href="/dc/council/laws/13-300.html">D.C. Law 13-300</a> repealed par. (2) which had read: “(2) Cannabis;”.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.13. Revising and republishing of schedules.</h1>
            <section>
              <section class="line-group primary-content">
                <p>The Mayor shall revise and republish the schedules semiannually for 2 years from August 5, 1981, and thereafter annually. The published schedules may include the brand or trade names of the substances controlled.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§213" title="§ 213.">Aug. 5, 1981, D.C. Law 4-29, § 213, 28 DCR 3081</a>.)
    </p>
                <h4>Prior Codifications</h4>
                <p>1981 Ed., § 33-523.</p>
                <h4>Section References</h4>
                <p>This section is referenced in <a class="internal-link no-wrap" href="/dc/council/code/sections/1-636.02.html">§ 1-636.02</a>.</p>
                <h4>Cross References</h4>
                <p>Effective date provisions, see <a class="internal-link no-wrap" href="/dc/council/code/sections/1-636.02.html">§ 1-636.02</a>.</p>
              </section>
            </section>
            <hr/>
            <h1>§ 48–902.14. Treatment of controlled substance analogues.</h1>
            <section>
              <section class="line-group primary-content">
                <p class="text-indent-1"><span class="level-num" id="(a)">(a)</span> A controlled substances analogue shall, to the extent intended for human consumption, be treated for the purposes of any District of Columbia law as a controlled substance in Schedule I.</p>
                <p class="text-indent-1"><span class="level-num" id="(b)">(b)</span> Except as provided in subsection (c) of this section, the term “controlled analogue” means:</p>
                <p class="text-indent-2"><span class="level-num" id="(b)(1)">(1)</span> a substance with a chemical structure that is substantially similar to the chemical structure of a controlled substance in Schedule I or II;</p>
                <p class="text-indent-2"><span class="level-num" id="(b)(2)">(2)</span> A substance that has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central system of a controlled substance in Schedule I or II; or</p>
                <p class="text-indent-2"><span class="level-num" id="(b)(3)">(3)</span> A substance that, with respect to a particular person, is represented to have or is intended to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to, or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of  a controlled substance in Schedule I or II.</p>
                <p class="text-indent-1"><span class="level-num" id="(c)">(c)</span> Such term does not include:</p>
                <p class="text-indent-2"><span class="level-num" id="(c)(1)">(1)</span> A controlled substance;</p>
                <p class="text-indent-2"><span class="level-num" id="(c)(2)">(2)</span> Any substance for which there is an approved new drug application;</p>
                <p class="text-indent-2"><span class="level-num" id="(c)(3)">(3)</span> With respect to a particular person any substance, if an exemption is in effect for investigational use, for that person, under § 505 of the Federal Food, Drug, and Cosmetic Act, approved June 25, 1938 (52 Stat. 1052, 21 U.S.C. § 355) to the extent conduct with respect to such substance is pursuant to such exemption; or</p>
                <p class="text-indent-2"><span class="level-num" id="(c)(4)">(4)</span> Any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.</p>
              </section>
              <br/>
              <section class="line-group annotations">
                <p>
      (<a class="internal-link" href="/dc/council/laws/4-29.html#§214" title="§ 214.">August 5, 1981, D.C. Law 4-29, § 214</a>; <a class="internal-link" href="/dc/council/laws/13-99.html" title="D.C. Law 13-99. Uniform Controlled Substances Amendment Act of 1999.">as added May 9, 2000, D.C. Law 13-99, § 2(b), 47 DCR 791</a>.)
    </p>
              </section>
            </section>
            <hr/>
          </section>
        </section>
      </div>
    </main>
    <footer>
      <section class="container center">
        <p>The codes and laws on this website are in the public domain.</p>
        <p>
              Please do not scrape. Instead, bulk download the <a href="https://github.com/dccouncil/dc-law-html">HTML</a> or <a href="https://github.com/dccouncil/dc-law-xml">XML</a>.
            </p>
        <p>Powered by the non-profit <a href="http://www.openlawlib.org/">Open Law Library</a>.</p>
      </section>
    </footer>
    <script type="text/javascript" src="/js/main.js"> </script>
  </body>
</html>
